Tirzepatide and the EU: why where you live shapes how you access it

Why EU tirzepatide isn't the shortcut it might seem

A common misconception worth clearing up gently: some people assume that because Mounjaro exists across Europe, buying or importing it from an EU country is a straightforward workaround for UK waiting lists or prices. It isn't. The UK's departure from the EU single market means that medicines follow separate regulatory and legal pathways here. The MHRA licenses medicines for the UK independently of EMA decisions, and a UK prescription (issued by a UK-registered clinician) is what makes dispensing legal on this side of the Channel.

That matters in practice. A prescription written by a doctor in France or Germany has no legal standing for a UK pharmacy. A pen purchased online from a European seller, with no UK clinical oversight, falls outside the licensed supply chain and offers you none of the safety guarantees that come with regulated dispensing. The MHRA has been explicit that medicines sourced this way carry real risks, including the possibility of counterfeit product. You can read more about how tirzepatide works and how it is prescribed in the UK if you want the full picture on the licensed route.

Eli Lilly holds marketing authorisations in both territories, but those are two separate legal instruments. The pens, the strengths, the leaflets, the supply chain, the pharmacovigilance reporting, all of it runs through different systems. Parallel importation for prescription medicines is tightly restricted under UK law, and for good reason.

How the two regulatory systems compare, and where they agree

Both the EMA and the MHRA reviewed the same body of clinical evidence before approving tirzepatide for weight management. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average body-weight reduction of around 20–21% at the 15mg dose over 72 weeks in adults with obesity. That evidence base underpins both approvals. The licensed indication (weight management alongside a reduced-calorie diet and increased activity, for adults with a BMI of 30 or above, or 27 or above with a weight-related health condition) is also broadly consistent across the two jurisdictions.

What differs is the governance around access. In the UK, NICE published its appraisal of tirzepatide (NICE technology appraisal TA1026) in December 2024, setting out the criteria for NHS use and confirming the clinical case for the medicine. Privately, UK patients can access tirzepatide through a GPhC-registered pharmacy following a clinical consultation, without needing to meet the more restrictive NHS thresholds. There is no equivalent private-prescription infrastructure running across EU borders for UK residents.

If you are considering treatment and want to understand the strengths available under the UK licence, our overview of Mounjaro in the UK covers the full dosing schedule factually. It is also worth knowing that patients sometimes ask whether Mounjaro or tirzepatide is the right way to think about their treatment options, since the two names refer to the same active ingredient under different contexts.

What this means if you are currently in the EU or moving between countries

If you live in the UK and travel to EU countries, your UK prescription does not allow a European pharmacy to dispense Mounjaro to you. Likewise, treatment started through a private UK service cannot simply be continued via an EU pharmacy while you are abroad. This is an area worth discussing with your prescriber before extended trips, not because the medicine changes, but because supply logistics and clinical oversight need to stay joined up. Our support team can help you think through the practicalities.

For people who have recently moved to the UK from an EU country and were already on tirzepatide, a UK-registered prescriber can review your existing treatment. Evidence of your current dose and clinical history would normally be requested as part of that assessment, and if you were on a higher maintenance dose you may find our guide to tirzepatide 30 and what that dose level involves a useful reference point. The nume FAQs cover what transfer patients need to bring to a consultation. The process is straightforward when the documentation is in order.

On the question of cost: tirzepatide pricing in EU countries varies considerably by market and reimbursement system, so EU prices are not a useful reference point for what you will pay in the UK. A more useful comparison is how UK private providers structure their pricing. Our Mounjaro price comparison page sets out what the UK private market looks like and what to read into headline figures.

The safe, legal route to tirzepatide in the UK

Given all of the above, the decision is fairly clear. If you are in the UK and clinically suitable, the path is: a consultation with a UK-registered prescriber, a prescription issued under UK law, and dispensing by a pharmacy registered with the GPhC. That is what the MHRA requires, and it is what protects you. For a clear explanation of the specific formulation used in the UK licensed supply chain, our page on tirzepatide l and how it relates to the dispensed product is worth a read. The MHRA's drug safety communications are worth reading if you want to understand the risks the regulator has flagged around medicines sourced outside licensed channels.

At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber on the same day it is submitted. There are no algorithms making clinical decisions. If treatment is appropriate, your prescription is processed and your order dispatched the same day, arriving free via tracked DPD delivery the next working day. You can verify our pharmacy on the GPhC register using premises number 9012878. If you would like to explore whether tirzepatide is right for you, the free consultation page is the place to start.